title: [CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications].
abstract: The study included 25 patients at high risk of thromboembolic complications. All of them were treated with acenocoumarol for 6 months under control of the frequency of hemorrhage and episodes of severe hypocoagulation (a more than 3-fold rise in INR). All the patients underwent CYP2C9 and VKORC1 genotyping. It was shown that the presence of CYP2C9*2 and CYP2C9*3 alleles in the CYP2C9 locus and the AA genotype of the polymorphous G-1639(3673)A marker of the VKORC1 gene was not associated with the development of severe hypocoagulation episodes (p = 0.261--for CYP2C9, p = 0.616 and 0.361 for VKORC1 in the total group and a subgroup of patients having the CYP2C9*1/*1 genotype respectively and treated with acenocoumarol. The search for other genetic markers of efficacy and safety of this drug should be continued.
authors.forename: D A
authors.initials: DA
authors.lastname: Sychev
authors.forename: I V
authors.initials: IV
authors.lastname: Ignat'ev
authors.forename: E S
authors.initials: ES
authors.lastname: Kropacheva
authors.forename: N V
authors.initials: NV
authors.lastname: Emel'ianov
authors.forename: V V
authors.initials: VV
authors.lastname: Milovanova
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Naumova
authors.forename: A V
authors.initials: AV
authors.lastname: Kosovskaia
authors.forename: O B
authors.initials: OB
authors.lastname: Dobrovol'skiĭ
authors.forename: A I
authors.initials: AI
authors.lastname: Tashenova
authors.forename: E P
authors.initials: EP
authors.lastname: Panchenko
authors.forename: V G
authors.initials: VG
authors.lastname: Kukes
mesh_terms: D000074:Acenocoumarol / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D001281:Atrial Fibrillation / Q000150:complications*; D015331:Cohort Studies; D065729:Cytochrome P-450 CYP2C9; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000235:genetics*; D011110:Polymorphism, Genetic; D012426:Russia; D013923:Thromboembolism / Q000139:chemically induced* / Q000235:genetics* / Q000517:prevention & control; D064417:Vitamin K Epoxide Reductases
chemical_list: D000925:Anticoagulants; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases; D000074:Acenocoumarol